To the Editor Prasad et al1 highlighted challenges related to the US Food and Drug Administration (FDA) accelerated approval of pembrolizumab use for patients with deficient mismatch repair gene expressing (dMMR) or microsatellite instability–high (MSI-H) solid tumors. It is important to clarify the accelerated approval basis and the opportunities resulting from the FDA-required confirmatory studies.
Sorscher S. Clarification of the FDA Accelerated Agnostic Approval of Pembrolizumab and the Opportunities Arising From the Required Confirmatory Studies. JAMA Oncol. 2018;4(9):1299–1300. doi:10.1001/jamaoncol.2018.1709
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: